Stevanato Group S.p.A. (STVN) saw its shares plummet 5.16% in Tuesday's intraday trading, despite reporting second-quarter earnings that largely beat analyst expectations. The sharp decline suggests that investors may be focusing on the company's forward guidance, which appears to have fallen short of market hopes.
The Italian medical packaging company reported Q2 2025 revenue of €280.0 million, surpassing the IBES estimate of €268.3 million. Net income came in at €29.7 million, slightly above the expected €29.2 million, while earnings per share met analyst projections at €0.11. Despite these positive results, the market's negative reaction indicates that investors were looking for even stronger performance or more optimistic future guidance.
Stevanato's outlook for the full year 2025 might be a key factor in the stock's decline. The company forecasts annual revenue between €1,160 million and €1,190 million, with adjusted EBITDA projected at €288.5 million to €301.8 million. This guidance, while solid, may have been perceived as conservative by investors who were anticipating more aggressive growth targets. The market's response underscores the high expectations placed on Stevanato Group, particularly in light of its recent stock performance, which had seen a 17.4% gain year-to-date prior to this earnings release.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.